A multicentre, randomized, parallel group, Phase 3 safety extension study to evaluate the safety and tolerability of benralizumab (MEDI-563) in asthmatic adults and adolescents on inhaled corticosteroid plus long-acting ss2 agonist (BORA)

Administered By

Awarded By

Contributors

Start/End

  • December 1, 2015 - November 30, 2018